Ms. Yang Min, currently a Partner at Zero2IPO Group and Managing Partner of Zero2IPO Industrial Investment, possesses over 20 years of experience spanning both industrial enterprises and financial investments. She now serves on the investment committees of multiple funds managed by Zero2IPO Group and holds directorships and advisory roles in several listed companies.

Prior to 2007, Ms. Yang held the position of Vice President at Zero2IPO Group, where she played an integral role in the development and standardization of China's early-stage equity investment industry. During her tenure, she amassed extensive industry connections and profound insights.

In 2007, Ms. Yang left Zero2IPO Group to successfully establish and operate two enterprises. Leveraging her exceptional business acumen and strategic execution capabilities, she sold these ventures, achieving a seamless integration of capital and industry. She rejoined Zero2IPO Group in 2014.

Drawing upon her deep professional expertise and rich industry experience, Ms. Yang excels in corporate management, strategic development, project investment, particularly in the convergence of industry and capital. She has conducted in-depth research and accumulated substantial practical experience in areas such as managing market value for listed companies, family asset management, and cooperation with government industrial funds. Her efforts have facilitated the establishment of industrial funds for numerous listed companies, promoting the coordinated development of capital and industry; assisted dozens of Chinese family businesses in setting up family funds to achieve wealth succession and value enhancement; and supported various local governments in establishing industrial funds, selecting high-quality enterprises suitable for regional development through professional judgment, realizing enterprise localization and equity appreciation exits via fund investments. Post-establishment, enterprises receive significant government support, accelerating growth and ultimately achieving a multi-win scenario for government, industry, and capital.

Ms. Yang has directly participated in investing in dozens of sub-funds and over a hundred companies, with notable cases including Henlius Biopharm, Guoke Tiancheng, MicuRx Pharmaceuticals, Ingenic Semiconductor, NewLink Group, Hankang Biotherapeutics, Health160, Shangde Education, Tongcheng Travel, Baibu, Pinchi Medical, and Bozhisoft Security, among others.